EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Inflammation-Associated Difficult-to-Treat Depression: Biomarkers and Precision Treatment Strategies

Bernhard T Baune

Journal of Inflammation Research · 2026-11 · Volume 19 · 1-22

DOI: 10.2147/jir.s635227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inflammation Research, 2026-11. Verfasst von Bernhard T Baune. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Difficult-to-treat depression (DTD) remains burdensome despite usual treatment efforts. Inflammation is a potential contributor in a subgroup, but heterogeneous signals, uncertain biomarker thresholds and nonstandardized patient selection limit translation.

Objective

This invited critical narrative review evaluates mechanisms, biomarkers and treatment evidence to clarify how inflammatory assessment could inform precision psychiatry without overstating causality or clinical readiness. Synthesis: Peripheral inflammatory measures, clinical features and metabolic comorbidity provide complementary but nonspecific information. Their association with persistent symptoms does not establish central neuroinflammation or identify a treatment-responsive endotype. Mechanistic findings implicate interacting neuroimmune, kynurenine, reward and stress pathways, with differing levels of human and preclinical support. Antidepressant-response associations must be distinguished from predictive treatment interactions. Immune-targeted trials provide mixed and preliminary evidence; subgroup or exploratory signals do not override null primary outcomes. The review proposes tiered biomarker assessment and separates established depression and comorbidity care from investigational inflammatory treatment selection.

Conclusion

Inflammation-associated DTD is best treated as a provisional stratification concept. Integrating repeated immune measures with clinical and metabolic information may improve the design of prospective treatment trials. Translation requires reproducible assays, validated selection rules, target engagement, patient-important outcomes and adequate safety evaluation. Biomarker-guided strategies must demonstrate benefit beyond usual care before routine implementation across diverse populations. Plain Language Summary: Depression is not one single biological condition. In some people whose depression remains burdensome despite usual treatments, the immune system appears to be persistently activated. This can sometimes be detected through blood markers such as C-reactive protein and inflammatory cytokines. These tests do not diagnose depression and they cannot prove that inflammation is the cause of a person’s symptoms. However, they may help identify a subgroup of people in whom inflammation contributes to fatigue, loss of pleasure, slowed thinking or movement, poor sleep, appetite and weight changes, pain, and physical health problems. This review explains how inflammation may contribute to difficult-to-treat depression, how inflammatory activity can be measured, and what is known about anti-inflammatory and immune-targeted treatment strategies. The key message is deliberately cautious. Inflammation may be relevant for a subgroup of people with persistent depression, but a single abnormal blood test should not be used to label someone as having an inflammatory form of depression. Better studies are needed to test whether selecting patients by repeated inflammatory markers and clinical features can improve treatment outcomes. Keywords: difficult-to-treat depression, depressive disorder, treatment-resistant, inflammation, biomarkers, c-reactive protein, precision medicine

Zitieren

APA

Baune, B. T. (2026). Inflammation-Associated Difficult-to-Treat Depression: Biomarkers and Precision Treatment Strategies. Journal of Inflammation Research, Volume 19, 1-22. https://doi.org/10.2147/jir.s635227

Vancouver

Baune BT. Inflammation-Associated Difficult-to-Treat Depression: Biomarkers and Precision Treatment Strategies. Journal of Inflammation Research. 2026;Volume 19:1-22. doi:10.2147/jir.s635227

BibTeX
@article{Baune2026,
  author = {Baune, Bernhard T},
  title = {Inflammation-Associated Difficult-to-Treat Depression: Biomarkers and Precision Treatment Strategies},
  journal = {Journal of Inflammation Research},
  year = {2026},
  volume = {Volume 19},
  pages = {1--22},
  doi = {10.2147/jir.s635227}
}
Kostenlos starten →